We subsequently further validated KV1.3 as a target for immunocytoprotection in ischemic stroke by demonstrating that pharmacological KV1.3 blockade and genetic KV1.3 deletion benefits young (16-week-old) and aged (80-week-old) mice of both sexes (Chen et al., 2021). The gene discussed is KCNA3; the disease is ischemic stroke.